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Abstract
Background: The diabetes epidemic is associated with huge human and economic costs, with some groups, such as 
indigenous populations in industrialised countries, being at especially high risk. Monitoring and improving diabetes 
care at a population level are important to reduce diabetes-related morbidity and mortality. A set of diabetes indicators 
has been developed collaboratively among the Organisation for Economic Co-operation and Development (OECD) 
countries to monitor performance of diabetes care. The aim of this review was to provide an overview of diabetes 
management in five selected OECD countries (Australia, Canada, New Zealand, the US and the UK), based on data 
available for general and indigenous populations where appropriate.
Methods: We searched websites of health departments and leading national organisations related to diabetes care in 
each of the five countries to identify publicly released reports relevant to diabetes care. We collected data relevant to 6 
OECD diabetes indicators on processes of diabetes care (annual HbA1c testing, lipid testing, renal function screening 
and eye examination) and proximal outcomes (HbA1c and lipid control).
Results: Data were drawn from 29 websites, with 14 reports and 13 associated data sources included in this review. 
Australia, New Zealand, the US and the UK had national data available to construct most of the 6 OECD diabetes 
indicators, but Canadian data were limited to two indicators. New Zealand and the US had national level diabetes care 
data for indigenous populations, showing relatively poorer care among these groups when compared with general 
populations. The US and UK performed well across the four process indicators when compared with Australia and New 
Zealand. For example, annual HbA1c testing and lipid testing were delivered to 70-80% of patients in the US and UK; 
the corresponding figures for Australia and New Zealand were 50-60%. Regarding proximal outcomes, HbA1c control 
for patients in Australia and New Zealand tended to be relatively better than patients in the US and UK.
Conclusions: Substantial efforts have been made in the five countries to develop routine data collection systems to 
monitor performance of diabetes management. Available performance data identify considerable gaps in clinical care 
of diabetes across countries. Policy makers and health service providers across countries can learn from each other to 
improve data collection and delivery of diabetes care at the population level.
Background
Magnitude of the diabetes epidemic in five selected 
countries
Diabetes mellitus is a significant health problem in many
countries, including Australia, Canada, New Zealand, the
United Kingdom (UK), and the United States (US). Table
1 shows the number of people affected by diabetes,
deaths due to diabetes, and estimated economic costs in
each of these five countries [1-7]. Absolute numbers of
people with diabetes (diagnosed and undiagnosed) varied
greatly from country to country. However, estimated
crude prevalence rates were consistently around 4%-6%,
and estimated crude case fatality ratios were between 2.5/
1000 and 3.8/1000 per year (these may not reflect the
quality of diabetes control across the nations as data col-
lection systems were different).* Correspondence: damin.si@menzies.edu.au1 Centre for Chronic Disease, School of Medicine, University of Queensland, 
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Page 2 of 19It is predicted that the number of people worldwide
with diabetes will double in the next generation [8]. As
well as the suffering of individuals and their families, dia-
betes poses a huge economic burden to nations' health
care systems, mostly due to expenditures relating to long
term diabetes complications and hospitalisations. In the
UK, it is estimated that the National Health Services
expenditure on diabetes will account for ten percent of its
total annual budget by 2011, double the level in 2004 (see
Table 1).
Due to such huge human and economic costs, nations
have intensified their efforts to combat diabetes. In Aus-
tralia, the National Diabetes Strategy was implemented in
1999, following the designation of diabetes as a National
Health Priority Area in 1996 [9]. The Canadian Diabetes
Strategy was initiated in 1999 with substantial invest-
ments to establish a national partnership for effective
prevention and control of diabetes [10]. Diabetes was
identified as one of the 13 Priority Population Health
Objectives in New Zealand in 2000, in an effort to reduce
the impact of diabetes and population health inequalities
[11]. In the US, the National Diabetes Education Program
was launched in 1997 to improve prevention and man-
agement of diabetes [12]. In the UK, a National Service
Framework for Diabetes was developed in 2003 with
explicit care standards and delivery strategies [13].
Diabetes epidemic among indigenous populations
Diabetes prevalence rates are much higher in indigenous
populations of high income ex-colonial countries than in
people of European origin. On average, American Indians
and Alaskan Natives are 2.3 times as likely to have diabe-
tes as non-Hispanic whites of similar age in the US [6]. In
Canada, prevalence of diabetes among First Nations peo-
ples is at least three times the national average [3], and
First Nations peoples with diabetes are 3-4 times more
likely to suffer from heart disease and stroke. Maori and
Pacific Island people in New Zealand have nearly three
times higher prevalence of diabetes, and their mortality
rates from diabetes in the 40-65 age group are nearly ten
times higher than for Europeans [4]. While Aboriginal
and Torres Strait Islander people in Australia experience
three to four times higher prevalence of diabetes than in
the general population [14], their death rate associated
with diabetes for the 35-54 years group is 27-35 times
that of non-Indigenous Australians [15].
Despite their diverse geographical locations, cultures
and traditions, the epidemic of diabetes among indige-
nous peoples is largely driven by rapid social and environ-
mental changes which aggravate preventable risk factors
such as unhealthy diet, decreased physical activity and
tobacco use [16]. The root causes of these lifestyle-related
risk factors are the long history of dispossession, exclu-
sion, discrimination and associated social and economic
disadvantage (including poor income, education, employ-
ment and living conditions) among indigenous popula-
tions [17].
Health systems performance for diabetes care
There is a renewed interest in developing and using qual-
ity indicators to measure and benchmark the perfor-
mance of health care systems with regard to diabetes
care. For example, National Health Priority Area diabetes
indicators have been employed to report national prog-
ress on prevention and control of diabetes in Australia.
Available data relating to such indicators were published
in 1998, 2002 and 2008 [1,18,19]. The US annual National
Healthcare Quality Report uses a set of 12 indicators to
assess national performance in diabetes management
[20]. Likewise, the US National Committee for Quality
Table 1: Diabetes prevalence, deaths due to diabetes, and economic costs in five selected countries*
Country Population†
(million)
People with 
diabetes 
(million)
Crude 
prevalence
No. of deaths due to diabetes Crude case fatality
ratio‡ (n/1000)
Costs/year 
(billion)
Primary cause Associated 
cause
Australia [1,2] 19.9 0.9 4.5% 3,329 8,138 3.7 AU$ 0.68
Canada [3] 32.5 1.7 5.2% 6,137 - 3.6 CA$ 1.60
New Zealand [4] 3.9 0.18 4.6% 802 - 4.5 NZ$ 0.18
UK [5] 60.2 2.8 4.7% 7,000 26,000 2.5 £ 3.50
US [6] 293.0 18.2 6.2% 69,308 143,754 3.8 US$ 132
* Data in the table refer to a period between 2002 and 2004.
† Populations were obtained from the International Data Base, US Census Bureau [7].
‡ Based on diabetes as primary cause of death.
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sure to assess the quality of diabetes services provided by
managed care plans (commercial insurance, Medicare
and Medicaid) [21]. Due to the diversity of the indictors
across countries, it has been difficult to conduct an inter-
national comparison of diabetes care.
Efforts in the development, specification, and field-test-
ing of measures for diabetes care have been carried out in
the form of international collaborations. The European
Union Diabetes Indicators Project was conducted during
2000-2002 and a set of core and secondary indicators was
proposed to monitor diabetes and its complications in
European Union/European Free Trade Area countries
[22]. An Organisation for Economic Co-operation and
Development (OECD) health technical paper delineates
recommended indicators for the quality of diabetes care
at the health system level in OECD countries [23]. These
indicators were selected using criteria assessing impact
on health, policy importance, susceptibility to being
influenced by the health care system, and feasibility of
data collection. As Australia, Canada, New Zealand, the
US, and the UK are all participating in the indicator
development and will be the future users of such mea-
sures, it is useful to assess the availability of data derived
from current systems to provide information for the indi-
cators.
Objectives of this review
(1) To assess the availability and quality of data which can
be used for constructing OECD diabetes indicators in five
selected countries (Australia, Canada, New Zealand, the
US, and the UK);
(2) To compare the quality of diabetes management at
the national level among these five countries using OECD
indicators; and
(3) To compare the quality of diabetes management
among indigenous populations in Australia, Canada, New
Zealand, and the US using these indicators.
Reasons for selecting these five countries in this review
include: 1) they are all OECD countries with advanced
economies; 2) indigenous health is an important issue in
Australia, Canada, New Zealand and the US; and 3) while
the UK is not related to the indigenous health issue, it has
a health care system similar to those in Australia, Canada
and New Zealand.
Methods
Search strategy for identification of data
A. Internet-based reports. As national level delivery of
services and quality of care data are usually published in
monographs or reports by health departments of national
governments, websites of the five countries' health
departments were first searched to identify publications
related to diabetes care. Then, the websites of the leading
national organisations relating to diabetes care in each
country were also searched to obtain relevant reports. A
list of internet sources for data searching is shown in
Table 2. The following terms were used for the search:
diabetes and (family practice, general practice, primary
care, outpatients, quality, audit, guideline adherence,
quality indicators, performance) (terms in the brackets
connected by or). The search was initially conducted in
May 2006 and updated in August 2009/February 2010.
We included reports released during the period January
2000 - July 2009. Only English reports were included in
this review.
B. The reference list of each retrieved report was also
scanned to identify relevant information sources.
Types of outcome measures
The OECD diabetes indicators were used to assess the
quality of diabetes management [23]. These nine indica-
tors cover clinical processes of diabetes care as well as
proximal and distal outcomes (Table 3). Notably, for
proximal outcomes, no specific cut-points for HbA1c and
LDL cholesterol have been recommended by the indica-
tor developers, reflecting a lack of international consen-
sus on the threshold levels of these outcome indicators.
The use of the six process and proximal outcome indica-
tors was based on robust evidence and international con-
sensus [23]. The use of the distal outcome indicators have
not been universally accepted due to operational con-
cerns. However, these distal outcomes represent long
term outcomes of diabetes care, providing insight into the
long term outcomes of overall health care systems.
We initially attempted to retrieve relevant information
from selected countries to construct all of these nine indi-
cators. However, we found that data for the three distal
outcome indicators were rarely available at the national
level, mainly due to difficulties in obtaining relevant
information on denominators (all patients with a diagno-
sis of diabetes) for these indicators. Therefore, this review
will only report results regarding the six process and
proximal outcome indicators.
Inclusion criteria
Types of data sources
Two types of data sources were included: routine data
collection systems in health care; and cross-sectional
studies (surveys). Cross-sectional studies or surveys are
generally considered to be suitable designs for evaluating
quality of health care [24].
Types of populations
'Study' populations were required to meet the following
three criteria:
1. With diagnosis of type 1 or type 2 diabetes;
2. Aged 16 years or more;
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provinces/states/regions).
Data that focused on gestational diabetes were
excluded.
Outcome measures
Data included were related to one or more of the six
OECD process and proximal outcome indicators as spec-
ified in Table 3.
Criteria for assessing data quality
We adapted a quality assessment tool for observational
studies developed by Wong et al [25]. The adapted tool
measured data quality in terms of sample representative-
ness, national coverage of data, measurement objective-
ness and response rate (see Additional file 1). An overall
quality assessment score is calculated to rate the data
Table 2: Internet sources for identification of diabetes-
related national reports in five selected countries
Country/Organisation Internet address
Australia
Department of Health and 
Ageing
http://www.health.gov.au
Australian Institute of 
Health and Welfare (AIHW)
http://www.aihw.gov.au/
HealthInsite http://www.healthinsite.gov.au/
topics/Diabetes
Australian Indigenous 
HealthInfoNet
http://www.healthinfonet. 
ecu.edu.au/
Australian Divisions of 
General Practice (ADGP)
http://www.adgp.com.au/site/
index.cfm
Primary Health Care 
Research & Information 
Service
http://www.phcris.org.au/
Diabetes Australia http://www.diabetesaustralia. 
com.au/
Australian Diabetes Society http://
www.diabetessociety.com.au/
International Diabetes 
Institute
http://www.idi.org.au/
home.htm
Canada
Health Canada http://www.hc-sc.gc.ca/english/
index.html
Canadian Institutes of 
Health Research
http://www.cihr-irsc.gc.ca
Canadian Diabetes 
Association
http://www.diabetes.ca/
National Aboriginal 
Diabetes Association
http://www.nada.ca/
Statistics Canada http://www.statcan.gc.ca/
New Zealand
Ministry of Health http://www.moh.govt.nz/
moh.nsf
New Zealand Health 
Information Service
http://www.nzhis.govt.nz
Diabetes New Zealand http://www.diabetes.org.nz/
The UK
Department of Health http://www.dh.gov.uk/Home/fs/en
Diabetes UK http://www.diabetes.org.uk/
National Electronic Library 
for Health
http://www.library.nhs.uk/
Audit Commission http://www.audit-commission. 
gov.uk/health/
The US
Department of Health and 
Human Services
http://www.hhs.gov
Centres for Disease Control 
and Prevention (CDC)
http://www.cdc.gov/diabetes/
Agency for Healthcare 
Research and Quality 
(AHRQ)
http://www.ahrq.gov
Indian Health Service (IHS) http://www.ihs.gov
Office of Minority Health 
Resource Center
http://www.omhrc.gov
National Committee for 
Quality Assurance (NCQA)
http://www.ncqa.org
American Diabetes 
Association (ADA)
http://www.diabetes.org
National Institute of 
Diabetes, Digestive and
Kidney Diseases (NIDDK) of 
the National Institutes
of Health (NIH)
http://www.niddk.nih.gov
Table 2: Internet sources for identification of diabetes-
related national reports in five selected countries 
Table 3: OECD diabetes indicators
Area Indicator name (number)
Processes of diabetes care (1) Annual HbA1c testing
(2) Annual LDL cholesterol testing
(3) Annual screening for 
nephropathy
(4) Annual eye examination
Proximal outcomes (5) HbA1c control
(6) LDL cholesterol control
Distal outcomes (7) Lower extremity amputation 
rates
(8) Kidney disease in persons 
with diabetes
(9) Cardiovascular mortality in 
patients with diabetes
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(0.67-1).
Review process and data abstraction
Initially, all reports/papers identified by the internet
search were screened by the reviewer (DS) against the
inclusion criteria, to identify potential reports/papers
which merited full-text reviews. A second reviewer (ZW)
repeated this process independently six months later for
selection of reports/papers into the review. The full
reports/papers that were identified as possibly meeting
the inclusion criteria by either reviewer were retrieved for
further assessment.
At the full-text level, a standardised abstraction form
was used independently by each reviewer to extract infor-
mation on data sources, targeted populations, outcomes,
and data quality. Any discrepancies of results between the
reviewers were resolved through discussion and consen-
sus.
When the same data sources provided multiple year
reports, all relevant reports were reviewed. However,
only the data from the most recent report (or from years
2005-2007 which most countries had data available) were
included in this review.
In this paper, unless otherwise specified, the term
"patients" refers to people diagnosed as having diabetes.
Results
One hundred and five reports/papers were initially iden-
tified by the internet search of 29 websites as specified in
Table 2) (Figure 1). Of those reports/papers, 36 met our
explicit inclusion criteria and their full-texts were
retrieved for data abstraction. During the full-text review,
22 reports/papers failed to meet inclusion criteria, and
the remaining 14 were included for the current review
[1,20,26-37].
Summary of identified data sources
The 14 reports related to 13 data sources which provided
information relevant to the 6 OECD diabetes indicators
(Table 4). These data sources can be broadly categorised
into three types: 1) medical record data - for example, the
General Practice Divisions Information Online System in
Australia, the Health Plan Employer Data and Informa-
tion Set in the US, and the National Diabetes Audit in the
UK; 2) administrative health insurance data, such as the
Health Insurance Commission General Practice Statistics
in Australia; and 3) population-based survey data - for
example, the Canadian Community Health Survey.
Appraisal of data quality
As detailed in Table 5, of the 13 data sources, two (13%)
were assessed as of poor quality, three (23%) as of satis-
factory quality, and eight (62%) as of good quality. The
poor quality of the two Australian data sources was
driven by lack of representativeness in sampling and rela-
tively low national coverage of the data.
Processes of diabetes care
Availability of data
Annual HbA1c testing, lipid testing, kidney function
examination, and eye examination rates are shown in
Tables 6 and 7. Four countries (Australia, New Zealand,
the US and the UK) had national data available for all of
these four process measures, but Canadian data were
available for only two process measures. Data sources
varied between countries: Australian data were mainly
derived from diabetes registers in general practice and
specialist clinics; Canadian data were based on the Cana-
dian Community Health Survey; the US data were col-
lected through the Health Plan Employer Data and
Information Set (HEDIS) using medical record audits; the
UK data were from the National Diabetes Audit; and New
Zealand data were from the National Get Checked Pro-
gramme. Except for Canada, the main data for the other
four countries are derived from health service records.
Comparison between countries
For across nation comparison, data need to be collected
using similar methods and during similar time periods.
Based on medical record data, the US and UK performed
relatively well across the four process indicators when
compared with Australia and New Zealand (Tables 6 and
7). For example, annual HbA1c testing and lipid testing
were delivered to 70-80% of patients in the US and UK;
the corresponding figures for Australia and New Zealand
were 50-60%.
Based on data from similar population level surveys in
Canada and US, the former had higher annual HbA1c
testing rate but relatively lower eye examination rate
when compared with the latter.
Sub-group comparison within countries
In Australia, annual checks for the four care processes
were consistently higher for patients receiving specialist
services than those cared for solely in general practice
(see Tables 6 and 7). Poor identification of Indigenous
status of patients in medical records limited the potential
to report corresponding data for Indigenous people.
Of diabetes patients registered in New Zealand, Pacific
Islanders had the highest annual HbA1c, lipid and kidney
function testing rates, followed by those of European ori-
gin. Delivery of the key processes of care to Maori people
was relatively low.
In the US, diabetes patients on Medicaid tended to have
lower annual checking rates for the four processes com-
pared to those on Medicare or commercial insurance.
Annual lipid testing and renal function examination rates
were substantially lower among American Indians and
Alaska Natives than general populations.
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Figure 1 Search results.
105 reports/papers identified through 
the internet search
36 Full reports/papers reviewed 
69 reports/papers rejected
            5 data sources did not meet inclusion criteria
          46 populations or conditions did not meet 
               inclusion criteria
          18 outcomes did not meet inclusion criteria
22 reports/papers excluded
16 outcomes were not of the most recent year for 
          the data source
3 populations did not meet inclusion criteria
3 outcomes did not meet inclusion criteria
14 reports/papers included in the review
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Country Data source/year Data collection method/frequency Availability of data for 
6 OECD indicators
Australia General Practice Divisions 
Information Online System 
2006-07 [26]
General Practice Divisions network includes 
about 120 regionally based divisions which 
facilitate and support active participation by 
GPs and general practices in primary care 
activities and programs. General practices' 
membership with regional divisions is 
voluntary. All Divisions network members are 
required to report against a set of National 
Performance Indicators (including 9 diabetes 
care related indicators). Diabetes care data are 
collected annually from practice level diabetes 
registers.
Indicators 1, 2, 5,6
National General Practice 
Divisions Diabetes Program, 
2002 [35,36]
The National General Practice Divisions 
Diabetes Program collected diabetes care data 
from 16 divisions who used the same 
electronic diabetes patient register (CARDIAB). 
GPs provided patient data for entry into 
divisional registers. Data were extracted from 
registers only for three years (2000, 2001 and 
2002). The project was one-off, with no 
ongoing data collection arrangement.
Indicators 1-6
Australian National Diabetes 
Information Audit & 
Benchmarking 2006 [27]
Diabetes specialist services are delivered 
primarily through over 60 Diabetes Centres 
across the nation, and relevant data are 
collected biennially by the National 
Association of Diabetes Centres through the 
Australian National Diabetes Information Audit 
and Benchmarking (ANDIAB) program. In 2006, 
15 Diabetes Centres and 1 specialist 
endocrinologist in private practice provided 
de-identified data on a total of 1624 individuals 
seen during the one-month survey period of 
October (or November) 2006.
Indicators 1-6
Health Insurance Commission 
General Practice Statistics, 
1999-2000 [1]
Australia has publicly funded, universal health 
insurance - Medicare. The computerised 
Medicare billing database records occasions of 
services provided by general practitioners and 
specialists. It contains information on service 
utilisation (e.g. laboratory investigations) for 
people with diabetes. However, the use of 
Medicare data to monitor diabetes care at the 
national level is on an ad hoc basis.
Indicators 1-4
The Australian Diabetes, 
Obesity, and Lifestyle Study 
(AusDiab), 1999-2000 [34,37]
The AusDiab was a population-based study of 
11,247 people from randomly selected areas of 
Australia in 1999-2000. Data collection 
methods included face-to-face interviews and 
physical and laboratory measurements. Data 
related to diabetes care were based on 439 
participants who had previously diagnosed 
type 2 diabetes. The study was a one-off 
national survey.
Indicators 4-6
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Survey 2005 [28]
A national, population-level periodical survey 
operated on a two-year data collection cycle, 
which includes diabetes-specific components 
(optional for inclusion at a province/territory 
level) in the questionnaire to collect data on 
diabetes care for those with self-reported 
diabetes in the general population. The 2005 
survey only collected diabetes care related 
data from six out of thirteen Canadian 
provinces/territories.
Indicators 1, 4
New Zealand National Get Checked 
Programme 2006 [29]
The nationally funded programme provides a 
free annual check for all people with a 
diagnosis of type 1 or type 2 diabetes. Services 
are delivered at the primary level by general 
practitioners or trained primary care nurses, 
and a particular effort has been made to ensure 
maximum access by Maori and Pacific Island 
peoples. Data are then passed to the Primary 
Health Organisations, which maintain registers 
for free annual checks and report aggregated 
datasets to the Local Diabetes Teams. Local 
Diabetes Teams combine data and provide 
annual reports to the District Health Boards 
and the Ministry of Health on an annual basis.
Indicators 1-6
The US Medical Expenditure Panel 
Survey (MEPS), 2004 [30]
The MEPS has two components: the household 
component and the insurance components. 
On an annual basis, the household component 
collects data from a nationally representative 
sample of families and individuals through 
household interviews. Information collected 
includes demographic characteristics, health 
conditions, health status, use of medical 
services, charges and source of payments, etc.
Indicators 1, 4
CDC Behavioural Risk 
Factor Surveillance System 
(BRFSS) [20]
The BRFSS is a state-based system of health 
surveys that collects information on health risk 
behaviours, preventive health practices, and 
health care access related to chronic disease 
and injury. Data are collected each year in all 50 
states and the District of Columbia, through 
telephone interviewing of a representative 
sample of more than 350,000 adults.
Indicators 1, 4
National Health and Nutrition 
Examination Survey 
(NHANES), 1999-2004 [30]
The NHANES collects information every few 
years on a national sample of approximately 
40,000 people using face-to-face interviews 
and physical and laboratory measurements. It 
asks participants whether they have a history 
of diabetes and performs blood analyses. The 
NHANES is valuable in generating national 
prevalence estimates for diabetes (diagnosed 
and undiagnosed) as well as in assessing 
cardiometabolic control among patients.
Indicators 5, 6
Table 4: Summary of identified data sources for constructing OECD diabetes indicators (Continued)
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lects information on Aboriginal status, the data on diabe-
tes care among Aboriginal populations had not been
reported at the time this review was completed.
Proximal outcomes
Availability of data related to HbA1c and lipid control
Four countries had data available to construct indicators
for HbA1c and lipid control at the national level (see
Tables 8 and 9). Australia and New Zealand data were
based on diabetes registers, the US used clinical audit
data from the HEDIS, and the UK data were obtained
through the National Diabetes Audit. Additionally,
HbA1c control data could be drawn from the periodical
National Health and Nutrition Examination Survey in the
US, and a national population-based survey (the Aus-
Diab) in Australia.
Comparison between countries
A number of different laboratory methods are used to
measure the HbA1c level, so the normal ranges for
Health Plan Employer Data 
and Information Set (HEDIS), 
2006 [31]
The HEDIS is a standardised tool used by the 
National Committee for Quality Assurance 
(NCQA) to collect performance data for 
managed care organisations. HEDIS data cover 
people enrolled in managed-care plans 
(commercial insurance, Medicare, and 
Medicaid). Commercial insurance is usually 
paid by employers for their employees, 
Medicaid covers certain individuals and 
families with low incomes, and Medicare is 
available for people 65 years or older as well as 
certain people with disabilities. Managed care 
organisations are the main source of health 
care services for persons with diabetes in the 
US. Data are collected annually by auditing 
clinical records.
Indicators 1-6
Indian Health Service, Clinical 
Reporting System, 2006 [32]
The Indian Health Service (IHS) is an agency 
within the US Department of Health and 
Human Services, providing health care services 
to eligible American Indian and Alaska Native 
people. The IHS reports to Congress each year 
on the quality of health care provided to its 
patients as required by the Government 
Performance and Results Act (GPRA). The GPRA 
measures comprise a set of clinical and non-
clinical indicators, including 6 indicators 
related to diabetes management. Data for the 
GPRA diabetes indicators are obtained 
through the IHS Clinical Reporting System 
which extracts information from individual 
patient health records at participating health 
facilities on an annual basis.
Indicators 1-6
The UK National Diabetes Audit 2005-
2006 [33]
The UK has established the National Clinical 
Audit Support Programme to assess current 
diabetes care at primary and secondary care 
sectors, and to review progress towards 
achieving the standards set out in the National 
Service Framework. In 2005-2006, 43% (131/
305) of Primary Care Trusts and 52% (102/196) 
of specialist paediatric units submitted data 
(with over 750,000 individual patient records) 
for the National Diabetes Audit. Data are 
extracted annually from the patient record 
systems in participating health care 
organisations.
Indicators 1-6
Table 4: Summary of identified data sources for constructing OECD diabetes indicators (Continued)
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Country Data source/year Quality assessment score
Sample 
representativeness
National coverage 
of diabetes care 
data
Measurement 
objectiveness
Response rate Overall score*
Australia General Practice Divisions 
Information Online 
System 2006-07 [26]
0
Voluntary 
participation by GPs 
and general practices
1
65% (77/119) of 
divisions provided 
data
1
Clinical records
Not applicable 0.66
National General 
Practice Divisions 
Diabetes Program, 2002 
[35,36]
0
Voluntary 
participation by GPs 
and general practices
0
13% (16/120) of 
divisions provided 
data
1
Clinical records
Not applicable 0.33
Australian National 
Diabetes Information 
Audit & Benchmarking 
2006 [27]
0
Convenience 
sampling of one 
month clinical 
encounter data
0
27% (16/60) of 
Diabetes Centres 
provided data
1
Clinical records
Not applicable 0.33
Health Insurance 
Commission General 
Practice Statistics, 1999-
2000 [1]
1
whole population 
data
1
Whole population 
coverage
1
Insurance 
billing data 
related to 
laboratory tests
Not applicable 1
The Australian Diabetes, 
Obesity, and Lifestyle 
Study (AusDiab), 1999-
2000 [34,37]
1
Stratified, multi-stage 
sampling
1
Nation wide
0.5
Interviews
Laboratory 
tests
1
> 60%
0.88
Canada Canadian Community 
Health Survey 2005 [28]
1
Stratified, multi-stage 
sampling
0
46% (6/13) of 
Canadian provinces/
territories provided 
data
0
Interviews
1
> 60%
0.50
New Zealand National Get Checked 
Programme 2006 [29]
1
Whole population 
data
1
64% of estimated 
diabetes patients in 
the country
1
Clinical records
Not applicable 1
The US Medical Expenditure 
Panel Survey (MEPS), 
2004 [30]
1
Representative 
sample of 
households
1
Nation wide
0
interviews
1
> 60%
0.75
CDC Behavioural Risk 
Factor Surveillance 
System (BRFSS) [20]
1
Representative 
sample of adults
1
Nation wide
0
Telephone 
interviews
1
> 60%
0.75
National Health and 
Nutrition Examination 
Survey (NHANES), 
1999-2004 [30]
1
Representative 
sample
1
Nation wide
0.5
Interviews
Laboratory
1
> 60%
0.88
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Page 11 of 19HbA1c may vary between laboratories. Moreover, vary-
ing cut-points used in different countries' reports make
international comparison difficult. For example, while
HbA1c < 7.0% was reported for Australia and the US
data, HbA1c < 8.0% was reported for New Zealand data,
and cut-points of < 6.5%, 6.5%-7.5% and > 7.5% were used
in the UK (Table 8). Most of the diabetes clinical guide-
lines [38-40] set HbA1c less than 7.0% as optimal glycae-
mic control.
Based on clinical data and allowing for adjustment of
differences in HbA1c cut-points used, glycaemic control
for patients in Australia and New Zealand appeared to be
relatively better than patients in the US and UK (Table 8).
Difficulties in comparing blood lipid control were
caused by the diversity of lipid parameters (total choles-
terol, low density lipoprotein cholesterol, high density
lipoprotein cholesterol, and triglycerides) and the varying
cut-points employed (Table 9). According to the clinical
guidelines from the US, New Zealand and Australia [38-
41], recommended optimal lipid control for diabetes
patients are as follows: total cholesterol < 4.0 mmol/L,
LDL-cholesterol < 2.6 mmol/L (or 2.5), HDL-cholesterol
> 1.0 mmol/L (or 1.1), and triglycerides < 1.7 mmol/L.
Using total cholesterol control among patients as an
example, the UK performed relatively better, followed by
Australia and the US (Table 9).
Sub-group comparison within countries
In Australia, patients in general practice were more likely
to have optimal HbA1c control than those visiting spe-
cialist clinics (57% versus 38%). However, this preliminary
comparison may not reflect true differences in the quality
of care in these two different settings, as patients referred
to specialist clinics tend to be those with uncontrolled
diabetes or more complications. Regarding blood lipid
control, patients visiting specialist diabetes clinics tended
to have better total cholesterol control compared those
cared for by GPs.
The proportion of New Zealand European patients
with HbA1c less than 8.0% was higher than that among
Maori or Pacific Islander counterparts (78% versus 56-
60%).
The US data revealed that patients on Medicaid were
more likely than those on Medicare or commercial insur-
ance to have poor blood glycaemic control and an ele-
vated LDL-cholesterol level. Control of HbA1c among
American Indian and Alaska Native patients (31% with
HbA1c < 7.0%) was poorer than that among general
patients (range 30-46%) in the US (Table 8).
Discussion
This internet-based review reveals that the five selected
countries have various data collection systems which, to
some extent, can be used to construct the OECD diabetes
indicators for cross country comparison. Routine data
collection mechanisms also allow countries to monitor
long-term trends of diabetes care. While New Zealand
and the US have relatively well developed data collection
systems to assess diabetes care among indigenous popu-
lations at the national level, Australia and Canada lag
behind substantially in this area and have no national
level diabetes care data available for indigenous popula-
tions. Countries can learn from each other to strengthen
data collection systems and to improve population-based
diabetes care.
Existing data sources for constructing OECD indicators: 
strengths and weaknesses
Diabetes registries
Australia and New Zealand have national data derived
from general practice diabetes registers to monitor utili-
Health Plan Employer 
Data and Information 
Set (HEDIS), 2006 [31]
1
Representative 
patient records from 
managed care 
organisations
1
90% of the US health 
plans provided data
1
Clinical records
Not applicable 1
Indian Health Service, 
Clinical Reporting 
System, 2006 [32]
1
All patient records 
from participating 
health facilities
1
All 12 Indian Health 
Service Areas 
provided data
1
Clinical records
Not applicable 1
The UK National Diabetes Audit 
2005-2006 [33]
1
All patient records 
from participating 
primary and 
secondary care 
sectors
0
43% (131/305) of 
Primary Care Trust 
and 52% (102/196) of 
specialist paediatric 
units provided data
1
Clinical records
Not applicable 0.66
* Grading of the quality assessment score: 0-0.33 (poor); 0.34-0.66 (satisfactory); 0.67-1 (good)
Table 5: Appraisal of data quality (Continued)
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Page 12 of 19sation of diabetes services. Diabetes registers are useful
vehicles for prospectively tracking patients, and data col-
lected are by-products of delivery of care. An issue of
concern is to what extent the register covers diabetes
populations. The registers covered 64% of estimated dia-
betes patients in New Zealand in 2006. However, the cor-
responding coverage information is unknown in
Australia. Provision of data by general practices on a vol-
untary basis in Australia may lead to substantial bias in
estimating population level indicators. Maximising cov-
erage of diabetes registers and participation of general
practices in data collection and reporting systems should
be a priority for future health information development
in Australia.
Administrative records: insurance billing data and electronic 
laboratory data
Administrative insurance data have been used in Austra-
lia and are planned to be used in Canada for surveillance
of diabetes services [42]. The use of insurance data has a
number of advantages, including: 1) coverage of nearly
the entire population, due to publicly funded health
insurance arrangements in these two countries; 2) these
data are not subject to recall bias; and 3) computerised
databases already exist. The use of Medicare occasions of
service data (1993-1997) in New South Wales (Australia)
was found to be a reliable, timely and cost-efficient way to
monitor health service utilisation for people with diabe-
tes [43]. All of the four diabetes process indicators could
be constructed using Medicare data at the national level
for Australia [1]. To date, the use of Australian Medicare
data to monitor diabetes care is on an ad hoc basis. If spe-
cific efforts are made to routinely analyse and report
Medicare data at the national level, information provided
for diabetes indicators will be valuable for policy makers,
health providers, researchers and the public to combat
and control diabetes. In the US, Medicare claims data are
Table 6: Annual HbA1c and lipid testing for people with diabetes by country
Country/Targeted population Annual HbA1c testing Annual lipid testing Data source
Australia
Patients in general practice diabetes 
registers
65% 50% General Practice Divisions Information 
Online System 2006-07 [26]
Patients visiting specialist diabetes 
clinics
93% 79% Australian National Diabetes 
Information Audit & Benchmarking, 
2006 [27]
Canada
Adults ≥ 18 years living in private 
households
74% - Canadian Community Health Survey 
2005 [28]
New Zealand
Patients on primary care diabetes 
registers
64% 64% National Get Checked Programme, 
2006 [29]
Subgroups: NZ European 68% 68%
Maori 39% 39%
Pacific Island 99% 99%
The US
Patients ≥ 40 years old 92% - Medical Expenditure Panel Survey, 
2004 [30]
Patients ≥ 18 years old with home 
telephones
61% - CDC Behavioural Risk Factor 
Surveillance System, 2001 [20]
Patients (18-75 years old) with 
Medicaid, Medicare, or Commercial 
Insurance
Medicaid: 78%
Medicare: 87%
Commercial: 88%
71%
85%
83%
Health Plan Employer Data and 
Information Set (HEDIS), 2006 [31]
American Indians and Alaska Natives 79% 60% Indian Health Service, Clinical 
Reporting System, 2006 [32]
The UK
Patients receiving care from primary 
and secondary care sectors
83% 81% National Diabetes Audit 2005-2006 [33]
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Page 13 of 19used by the Centres for Medicare and Medicaid Services
to monitor quality of diabetes care for Medicare benefi-
ciaries [44].
The Canadian National Diabetes Surveillance System
[42] is a national standardised database linking three
types of person-specific administrative data (Physician
Claims File, Hospital File and Health Insurance Registry).
The first report from the Canadian National Diabetes
Surveillance System contained prevalence and mortality
data. The 2008 report provides information on health
services utilisation in terms of the number of visits to
family physicians and specialists by patients [45]. Further
development of the system has the potential to report
national diabetes care data related to the four process
indicators used in this review. Importantly, at the Cana-
dian province level, there has been reported use of clini-
cal and administrative data to evaluate diabetes care in
terms of process indicators (e.g. in British Columbia)
[46].
One of the disadvantages in using administrative insur-
ance data is that these data include only information on
those who use health services; for people with diabetes,
only those with a diagnosis from a health professional are
included. Also, administrative data lack detailed informa-
tion on characteristics of patients such as ethnicity, which
prevents related sub-group analysis. Another drawback is
Table 7: Annual kidney function and eye examination for people with diabetes by country
Country/Targeted 
population
Annual kidney function 
examination
Annual eye examination Data source
Australia
General patients - 77% (2 yrs) The Australian Diabetes, Obesity, 
and Lifestyle Study [34]
Patients in GP diabetes 
registers
27% 32% National Divisions Diabetes 
Program, 2002 [35,36]
Patients visiting specialist 
diabetes clinics
70% - Australian National Diabetes 
Information Audit & 
Benchmarking, 2006 [27]
Patients whose tests were 
processed by Medicare
18% 70% (2 yrs) Health Insurance Commission 
General Practice Statistics, 1999-
2000 [1]
Canada
Adults ≥ 18 years living in 
private households
- 48% Canadian Community Health 
Survey 2005 [28]
New Zealand
Patients on primary care 
diabetes registers
64% 71% (2 yrs) National Get Checked Programme, 
2006 [29]
Subgroups: NZ European 68% 73% (2 yrs)
Maori 39% 68% (2 yrs)
Pacific Island 99% 66% (2 yrs)
The US
Patients ≥ 40 years old - 68% Medical Expenditure Panel Survey, 
2004 [30]
Patients ≥ 18 years old with 
home telephones
- 67% CDC Behavioural Risk Factor 
Surveillance System, 2001 [20]
Patients (18-75 years old) with 
Medicaid, Medicare, or 
Commercial Insurance
Medicaid: 75%
Medicare: 85%
Commercial: 80%
51%
62%
55%
Health Plan Employer Data and 
Information Set (HEDIS), 2006 [31]
American Indians and Alaska 
Natives
55% 49% Indian Health Service, Clinical 
Reporting System, 2006 [32]
The UK
Patients receiving care from 
primary and secondary care 
sectors
83% 61% National Diabetes Audit 
2005-2006 [33]
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Page 14 of 19that insurance data do not record the test results, for
example, HbA1c and total cholesterol levels.
Electronic laboratory data are becoming more common
in many OECD countries. Therefore, it is possible to con-
struct measures for HbA1c and lipid control from such
data sources. The challenge is how to link these data with
other data such as insurance billing records using a
unique identifier for individual patients.
Auditing medical records
As illustrated in this review, data collection systems such
as National Clinical Audit in the UK and the HEDIS in
the US, which obtain data through auditing of medical
records, provide all the information needed for the six
OECD diabetes process and proximal outcome indica-
tors. The quality of data from the clinical audits is gener-
ally good. With a more widespread use of electronic
medical records, clinical auditing will be less labour-
intensive and more feasible to provide population-based
information on diabetes care.
The HEDIS data cover people enrolled in managed-
care plans of different types (commercial insurance,
Medicare, and Medicaid), but do not cover people with-
out health insurance (estimated to be 45 million in the
US, accounting for 16% of the whole population) [31]. A
published national study sheds new light on the quality of
health care (including diabetes care) delivered to adults in
the US [47]. Based on reviews of medical records, the
study found that adherence to the processes relating to
six monthly HbA1c testing, ever-documented total cho-
lesterol test, annual urine protein test, and annual eye
examinations, were 24%, 58%, 24%, and 14%, respectively.
These results were apparently lower than those reported
by managed-health plans, indicating quality of diabetes
care is lower in the nation as a whole than in those people
with health insurance.
Periodical national health surveys
The Behavioural Risk Factor Surveillance System (BRFSS)
in the US and the Canadian Community Health Survey
collect data annually and every two years respectively,
based on interviews of participants. While reporting pop-
ulation based diabetes care process information on a reg-
ular and ongoing basis is a major strength of those
surveys, recall biases from respondents and lack of infor-
mation on outcomes (such as HbA1c control) are the
Table 8: HbA1c control for people with diabetes by country
Country/Targeted population Criteria Percent Data source
Australia
Patients in GP diabetes registers HbA1c < 7.0% 57% General Practice Divisions Information Online System 2006-07 [26]
Patients visiting specialist 
diabetes clinics
HbA1c < 7.0% 38% Australian National Diabetes Information Audit & Benchmarking, 
2006 [27]
General patients HbA1c < 7.0% 57% AusDiab 1999-2000 [37]
Canada - -
New Zealand
Patients on primary care 
diabetes registers
HbA1c < 8.0% 73% National Get Checked Programme, 2006 [29]
Subgroups: NZ European 78%
Maori 60%
Pacific 56%
The US
Patiens≥ 40 years old HbA1c < 7.0% 49% National Health and Nutrition Examination Survey (NHANES), 
1999-2004 [30]
Adults (18-75 years old) with 
Medicaid, Medicare, or 
Commercial Insurance
HbA1c < 7.0%
Medicaid
Medicare
Commercial
30%
46%
42%
Health Plan Employer Data and Information Set (HEDIS), 2006 [31]
American Indians and Alaska 
Natives
HbA1c < 7.0% 31% Indian Health Service, Clinical Reporting System, 2006 [32]
The UK
Patients receiving care from 
primary and secondary care 
sectors
HbA1c < 6.5%
HbA1c 6.5-7.5%
HbA1c > 7.5%
22%
36%
42%
National Diabetes Audit 2005-2006 [33]
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Page 15 of 19major weaknesses. The US National Health and Nutrition
Examination Survey (NHANES) collects data using inter-
views and laboratory tests, lending its capacity to report
HbA1c and lipid control among patients with diabetes.
In Australia, the National Health Survey (NHS) pro-
vided data for estimating prevalence of self-reported dia-
betes. However, it does not have diabetes-specific
components in the questionnaire that allow further anal-
ysis of utilisation of diabetes services. The Australian Dia-
betes, Obesity, and Lifestyle Study (AusDiab) was a one-
off population-based survey, ruling out its ability to mon-
itor diabetes care over time.
Our assessment of quality of data sources included in
the review showed that the majority of them (11/13) were
of satisfactory or good quality. This should encourage
policy makers, administrators, and service providers to
continue their efforts and investments in the routine data
collection systems for ongoing monitoring and improving
diabetes care. The poor quality of the two data sources
was largely due to poor representativeness in sampling
and low national data coverage, highlighting the areas for
improvement in the data collection systems.
Strengths and limitations of the present review
We primarily searched websites of health departments
and leading national organisations related to diabetes
care in each of the five countries, to identify publicly
released reports relevant to diabetes care. With the inter-
net playing a significant role in access to and dissemina-
tion of information, the search strategy used was well
suited to the aims of the review.
This review is subject to some limitations. Due to the
evolving nature of website contents (information is added
or removed from time to time), there was possibility that
some relevant reports might not be captured by the inter-
net search. We updated the search in 2009/2010 after the
initial search in 2006 to minimise this limitation.
Caveats in interpreting OECD diabetes indicators
Tensions between diabetes performance indicators and 
clinical practice guidelines
Diabetes clinical guidelines are intended to set optimal
standards of care for individual patients by accounting for
age and severity of the disease. Unlike clinical guidelines,
performance indicators focus on measuring quality of
care at a population level and creating a basis for account-
ability and quality improvement in the health care system
[48]. In patients with a variety of disease states, compari-
son of care across healthcare systems becomes difficult if
important confounders (e.g. patients' age and health sta-
tus) are not adjusted for.
Table 9: Lipid control for people with diabetes by country
Country/Targeted population Criteria Percent Data source
Australia
Patients in GP diabetes registers TC < 4 mmol/lL 44% General Practice Divisions Information Online 
System 2006-07 [26]
Patients ≥25 years old TC≥5.5 mmol/L
HDL-C < 1.0 mmol/L
Triglycerides > 4.0
Male
58%
22%
8%
Female
69%
24%
7%
AusDiab 1999-2000 [37]
Patients visiting specialist 
diabetes clinics
TC≥5.5 mmol/L
LDL-C≥2.6 mmol/L
14%
82%
Australian National Diabetes Information Audit & 
Benchmarking, 2006 [27]
Canada - -
New Zealand - -
The US
Patiens≥ 40 years old TC < 5.2 mmol/L
LDL-C < 2.6 mmol/L
48% National Health and Nutrition Examination 
Survey (NHANES), 1999-2004 [30]
Patients (18-75 years old) with 
Medicaid, Medicare, or 
Commercial Insurance
Medicaid
Medicare
Commercial
31%
47%
43%
Health Plan Employer Data and Information Set 
(HEDIS), 2006 [31]
The UK
Patients receiving care from 
primary and secondary care 
sectors
TC < 5 mmol/L 73% National Diabetes Audit 2005-2006 [33]
TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
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tors reflect a level of care which is less than the ideal stan-
dard, to facilitate comparison across populations without
a need for risk adjustment [48]. For example, with regard
to frequency of HbA1c testing, the American Diabetes
Association's guidelines recommend that HbA1c testing
be performed at least once every six months for people
with stable blood glucose levels and every three months
in those whose therapy has changed or who are not meet-
ing blood glucose goals [38]; performance indicators,
however, only measure whether HbA1c has been tested at
least once in the last 12 months.
While clinical guidelines play an essential role in pro-
moting best quality of care for individuals, performance
indicators have been primarily employed in an attempt to
reflect quality of care at the population level in a conve-
nient and feasible way. It is important to avoid interpreta-
tion of indicators as definitions of the "standard of care".
Blood pressure control and foot examination: forgotten areas
The current proposed OECD indicators do not cover ser-
vices relating to blood pressure control and foot examina-
tions, as these indicators are perceived as not feasible to
collect from administrative data sources.
However, in this review, it was found that the most reli-
able and comprehensive data for current use were
obtained from auditing medical records. It is possible to
extract data on blood pressure control and foot examina-
tions through this approach.
Therefore, inclusion of blood pressure control and foot
examinations in the spectrum of OECD indicators would
provide a holistic profile regarding quality of diabetes
care. Exclusion of these indicators may risk underestimat-
ing their importance in clinical practice and discourage
efforts to collect relevant data.
Treatment for patients with diabetes
It is notable that treatment of diabetes has not been
directly monitored by OECD indicators, largely due to
complexity in data collection. Treatment is tailored for
individuals depending on the patient's disease status, and
plays a crucial role in diabetes management. Clinical tri-
als have found that a one percentage point reduction in
HbA1c levels would reduce micro-vascular complications
by 25% to 30% [49,50] and a 10 mmHg reduction in blood
pressure would decrease macro- and micro-vascular
complications and death rates by 32% [51]. Improved
control of blood lipids can reduce risk of coronary heart
disease by 39% and risk of death by 43% [52].
RAND's Quality Assessment Tools System offers indi-
cators relating to diabetes treatment [53], and application
of these indicators in a national study in the US has pro-
vided insight into adherence to recommended treatment
regimens. For people with newly diagnosed diabetes 56%
received dietary and exercise counselling. In type 2 diabe-
tes patients, use of oral hypoglycaemic agents for those
inadequately controlled on dietary therapy was 38% and
use of insulin for those inadequately controlled on oral
hypoglycaemics was 39%. Fifty-five percent of diabetics
were offered an ACE inhibitor within 3 months of the
notation of proteinuria unless contraindicated.
The AusDiab study reported the treatment pattern
among Australian adults with type 2 diabetes [37]. While
32% of diabetes patients were on diet regimen only, 58%
used oral hypoglycaemic agents and diet only, and
another 10% took insulin. Bailie and colleagues reported
pharmaceutical interventions for diabetes patients in
remote Aboriginal communities in the Northern Terri-
tory [54]. During the 3-years study period, 75-79% of
Aboriginal patients took oral hypoglycaemic agents, and
4-7% used insulin.
Comparison of diabetes care and health system 
performance across countries
Allowing for the difference in data collection methods,
there was relatively wide variation in performance related
to processes of diabetes care across the five countries. For
example, annual HbA1c testing rates were 64-65% in New
Zealand and Australia; the corresponding rate for the UK
was 83%. Relatively better performance in such indicators
in the UK general practice may be partly due to payment
based on capitation, which requires general practitioners
to clearly define a population and take a population-
based approach to clinical care [55]. In contrast, most
general practitioners in Australia are paid on a fee-for-
service basis, with no clearly defined populations for ser-
vice delivery.
However, relatively less variation was observed in rela-
tion to proximal outcomes such as HbA1c control across
the countries. To achieve HbA1c control targets as set by
clinical guidelines is much more complicated than to sim-
ply test HbA1c levels. Previous studies comparing pri-
mary care and health system performance in these five
countries have identified common deficiencies in health
care systems, including poor care coordination and defi-
cient patient-doctor communication [56,57]. These can
result in duplicate tests, delays in care, failure of doctors
to discuss care goals and options with patients and to
review medication regimens. Such widespread deficien-
cies across the five countries are likely to contribute to
the suboptimal control of HbA1c among patients.
In a recently published OECD Health at a Glance 2009
report [58], two diabetes-related indicators [admission
rates for acute diabetic complications; diabetes lower
extremity amputation rates (denominators were general
populations rather than peoples with diabetes as speci-
fied in the original indicator set listed in Table 3)], along
with the other 21 indicators, have been used to measure
health system performance across OECD countries. Dia-
betes lower extremity amputation rates were higher in the
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Page 17 of 19US (36/100,000 population) than in New Zealand, Can-
ada and the UK (9-12/100,000), as were admission rates
for acute diabetic complications (57/100,000 versus 1-32/
100,000). It appeared that diabetes management might be
much poorer at the primary care level in the US which led
to substantially higher rates of diabetes-related complica-
tions. Our review provided evidence of relatively poor
control of HbA1c among patients in the US, a direct mea-
sure of diabetes management in primary care. With avail-
ability and comparability of data up to standard in the
future, inclusion of indicators such as HbA1c testing and
control into selected OECD health care quality indicators
for reporting would enhance understanding of variation
in health system performance across countries and point
to ways for improvement.
Implications for practice and policy
Measured by OECD diabetes indicators, considerable
gaps were revealed in the five selected countries in rela-
tion to both optimal diabetes care and availability/quality
of data. Countries can learn from each other to
strengthen these areas.
For Australia, one of the priorities is to strengthen rou-
tine data collection and reporting systems using diabetes
registers in general practice, and to improve the coverage
of the diabetes registers.
In line with the national funding plan to implement
"Strategies for the prevention and control of diabetes in
New Zealand", specific funding has been allocated to
Maori and Pacific Island people for their own initiatives,
including annual free checks and treatment. This desig-
nated financial arrangement increased access to high
quality diabetes care for Maori and Pacific peoples as well
as availability of information. Further implementation of
the programme in New Zealand should increase its reach
to indigenous and non-indigenous populations in the
country. The national diabetes clinical audit system in the
UK proves to be a feasible and efficient information sys-
tem in monitoring diabetes care.
In the US, the most comprehensive and timely data are
reported by the National Committee for Quality Assur-
ance to measure performance of managed care plans
through the HEDIS. The US Indian Health Service has a
well developed Clinical Reporting System to routinely
support diabetes care data for American Indians and
Alaska Natives. However, for Canada, performance in
most key indicators is currently unknown at the national
level. Further development of the Canadian National Dia-
betes Surveillance System might serve as a vehicle to nar-
row the current information gap.
There is an urgent need for diabetes care information
among indigenous populations in Australia and Canada.
The process and proximal indicators provide information
to inform efforts for prevention and early detection of
diabetes-related complications. However, the evidence in
this review is especially deficient in these areas for indige-
nous populations in Australia and Canada. Based on New
Zealand and US experiences, with specific commitment
to data collection for indigenous populations through
effective policy and legislation, it is possible to obtain
parallel information for these populations in relation to
key indicators of diabetes care.
Conclusions
Substantial efforts have been made in the five countries to
develop routine data collection systems to monitor per-
formance of diabetes management. Available perfor-
mance data identify considerable gaps in clinical care of
diabetes across countries. Policy makers and health ser-
vice providers across countries can learn from each other
to improve data collection and delivery of diabetes care at
the population level.
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